SEC Comment Letter 0000000000-24-013994 to Salarius Pharmaceuticals, Inc. (SLRX) (CIK 0001615219) (DCOY)
Salarius Pharmaceuticals, Inc. (SLRX) (CIK 0001615219)
Date: Dec. 18, 2024 · CIK: 0001615219 · Accession: 0000000000-24-013994
AI Filing Summary & Sentiment
File numbers found in text: 333-283828
Letter
December 18, 2024 David J. Arthur President and Chief Executive Officer Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd. Suite X Houston, TX 77021 Re:Salarius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 16, 2024 File No. 333-283828 Dear David J. Arthur: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Stephen Nicolai, Esq.
Show Raw Text
December 18, 2024
David J. Arthur
President and Chief Executive Officer
Salarius Pharmaceuticals, Inc.
2450 Holcombe Blvd.
Suite X
Houston, TX 77021
Re:Salarius Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 16, 2024
File No. 333-283828
Dear David J. Arthur:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Stephen Nicolai, Esq.